- A retrospective case-series finds an overall response rate (ORR) of 37% in patients given gemcitabine-based salvage chemotherapy for relapsed and refractory non-Hodgkin lymphoma (R/R NHL).
Why this matters
- Most studies report 50% or better ORR in this patient population.
- Better therapies are urgently needed.
- Retrospective, consecutive case-series of 41 patients with R/R aggressive NHL given gemcitabine-based regimens from 2007 to 2015 at an Israeli hospital.
- Funding: None disclosed.
- Median follow-up was 218 days; median age was 66.4 years.
- 73% of patients had B-cell and 27% had T-cell NHL; all had received a median of 2 prior regimens, 1 of which was anthracycline-based.
- The ORR was 36.6%, with 24.4% having complete response and 12.2% having partial response; the remainder had progressive or stable disease.
- Median PFS was 47 days (range, 12-1318 days); median OS was 1.9 years (range, 0.03-4 years).
- Treatment with a full-dose regimen was associated with superior OS (χ2, 7.33; P=.007).
- 51.2% had grade 3-4 hematological toxicity.
- 48.8% of patients died during follow-up.
- Single-center study.
- Observational design.